Alzheimer’s Disease

Alzheimer’s disease is the most common form of dementia, accounting for 60–80 percent of cases worldwide. It is a progressive neurodegenerative disorder that impairs memory, language, and decision-making, often leading to years of disability and caregiving. While recent FDA-approved therapies may slow the onset of cognitive decline, they are not curative, and access remains limited. Diagnosis often comes too late, and no approved treatments yet target tau pathology or other key drivers of disease.

SPARC has worked for nearly a decade to accelerate progress in Alzheimer’s. Through strategic partnerships, we support targeted philanthropic investment, advance next-generation research and care, and foster interdisciplinary leadership across data science and neuroscience. These efforts aim to close gaps, empower stakeholders, and build a more coordinated and effective Alzheimer’s ecosystem.